PSNL

Personalis Inc

15.73

Nov 06 • 10:11 AM ET +0.18 (1.16%)

Healthcare Diagnostics & Research USA Small NASD

Nov 04, 4:40 PMPersonalis posts Q3 2026 net loss $33.8M ($0.32/share) on revenue $25.6M, up 77% YoY and above estimates

Peers: NTRA GH NEO ADPT VCYT TEM BLLN GRAL FLGT CAI

| Held by: VTI IWM VXF IWN IBB DFAS VTWO SCHA DFMC IWC

Scroll to Statements

Index	RUT
Market Cap	1.71B
Enterprise Value	1.55B
Income	-119.33M
Sales	80.77M
Book/sh	1.96
Cash/sh	1.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	260
IPO	Jun 20, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	21.11
P/B	8.02
P/C	8.95
P/FCF	-
EV/EBITDA	-
EV/Sales	19.21
Quick Ratio	4.38
Current Ratio	4.51
Debt/Eq	0.17
LT Debt/Eq	0.14
Option/Short	Yes / Yes

EPS (ttm)	-1.16
EPS next Y	-0.99
EPS next Q	-0.24
EPS this Y	-20.15%
EPS next Y	9.45%
EPS next 5Y	6.66%
EPS past 3/5Y	28.38% 2.91%
Sales past 3/5Y	2.30% -2.40%
EPS Y/Y TTM	-32.64%
Sales Y/Y TTM	16.88%
EPS Q/Q	-29.17%
Sales Q/Q	76.59%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	-21.53% 18.82%

Insider Own	32.64%
Insider Trans	-1.61%
Inst Own	59.59%
Inst Trans	2.80%
ROA	-44.66%
ROE	-62.14%
ROIC	-49.32%
Gross Margin	16.71%
Oper. Margin	-156.66%
Profit Margin	-147.74%
SMA20	-0.66%
SMA50	-2.77%
SMA200	37.62%
Trades

Shs Outstand	108.38M
Shs Float	73.01M
Short Float	9.30%
Short Ratio	2.48
Short Interest	6.79M
52W High	18.89 -16.73%
52W Low	4.95 217.46%
Volatility	1.60% 1.73%
ATR (14)	0.31
RSI (14)	44.79
Beta	2.35
Rel Volume	2.08
Avg Volume	2.73M
Volume	853,914

Perf Week	-0.57%
Perf Month	-2.05%
Perf Quarter	8.48%
Perf Half Y	163.04%
Perf YTD	97.61%
Perf Year	118.93%
Perf 3Y	1383.96%
Perf 5Y	-23.53%
Perf 10Y	-
Recom	3.00
Target Price	16.25
Prev Close	15.55
Price	15.73
Change %	1.16%

Consensus

Hold

Avg. Price Target

$16.25

Implied Upside

+3.3%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2026	Downgrade	BBTIG Research	Buy → Neutral
Aug 24, 2026	Downgrade	CCraig Hallum	Buy → Hold	$16.25	+3.3%
Dec 02, 2025	Resumed	MMorgan Stanley	Equal-Weight	$11	-30.1%
May 15, 2025	Initiated	GGuggenheim	Buy	$6	-61.9%
Mar 17, 2025	Initiated	CCraig Hallum	Buy	$8	-49.1%
Feb 06, 2023	Upgrade	NNeedham	Hold → Buy	$8	-49.1%
Feb 06, 2023	Upgrade	NNeedham	Hold → Buy
Jan 07, 2022	Upgrade	BBofA Securities	Neutral → Buy	$27 → $23	+46.2%
Nov 05, 2021	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
Nov 03, 2021	Downgrade	NNeedham	Buy → Hold
Oct 15, 2021	Resumed	CCowen	Outperform
Sep 20, 2021	Reiterated	NNeedham	Buy	$33 → $28	+78.0%
May 06, 2021	Upgrade	OOppenheimer	Perform → Outperform	$28	+78.0%
Jan 28, 2021	Initiated	TTruist	Buy	$50	+217.9%
Jan 04, 2021	Downgrade	BBofA Securities	Buy → Neutral	$40	+154.3%
Nov 12, 2020	Reiterated	NNeedham	Buy	$25 → $32	+103.4%
Nov 06, 2020	Downgrade	OOppenheimer	Outperform → Perform
Oct 19, 2020	Initiated	CCitigroup	Buy	$35	+122.5%
Oct 08, 2020	Initiated	BBTIG Research	Buy	$35	+122.5%
Aug 27, 2020	Initiated	HH.C. Wainwright	Buy	$30	+90.7%

Nov-04-26 04:28PM	Personalis: Q3 Earnings Snapshot (Associated Press)
03:01PM	Personalis Reports Third Quarter Results (Business Wire)
Nov-02-26 08:11AM	Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer (Barrons.com)
07:00AM	Tempus Reports Third Quarter 2026 Results (Business Wire)
Oct-30-26 09:41AM	Are PAG, BRBS, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:52PM	Loading…
Oct-27-26 12:52PM	Are BWMN, PAG, CCC, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
Oct-22-26 12:33PM	Are VRNS, DSGR, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
Oct-21-26 06:00AM	Personalis NeXT Personal Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 (Business Wire)
Oct-20-26 06:00AM	Personalis Brings Resistance Mutation Tracking to NeXT Personal MRD Test (Business Wire)
Sep-09-26 02:49PM	Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-04-26 11:21AM	Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? (PR Newswire)
05:30AM	The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. (The Wall Street Journal)
Sep-01-26 09:45AM	Piper Sandler Lifts Tempus AI to Overweight at $76 (GuruFocus.com)
09:36AM	Tempus AI shares rise 2.7% following analyst actions (InvestorsHub)
Aug-20-26 01:22PM	TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight (Stocktwits) +6.77%
01:49PM	Loading…
Aug-19-26 01:49PM	TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial (Stocktwits) +13.66%
Aug-04-26 04:08PM	Personalis: Q2 Earnings Snapshot (Associated Press)
04:01PM	Personalis Reports Second Quarter Results and Recent Highlights (Business Wire)
12:52PM	Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-27-26 07:39PM	Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-21-26 02:50PM	Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:40AM	Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal (Quartz)
08:30AM	Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion (Quartz)
07:43AM	Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal (Medical Device Network)
Jul-20-26 04:56PM	Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal (GuruFocus.com) -13.32%
03:38PM	TEM, PSNL Stocks Are Falling Why Morgan Stanley Still Likes Tempus AIs Personalis Deal (Stocktwits)
12:06PM	Cathie Wood Dumps $39 Million Worth of AMD Stock (GuruFocus.com)
11:23AM	Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B (Proactive)
11:11AM	TEMs Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity Retail Awaits To See Execution (Stocktwits)
08:35AM	Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
07:27PM	Loading…
Jul-16-26 07:27PM	Why Is PSNL Stock Up 5% After-Hours? (Stocktwits)
Jul-14-26 06:00AM	Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal, Expanding MRD Access and Biopharma Support in Great Britain (Business Wire)
Jun-09-26 06:00AM	Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits (Business Wire)
Jun-02-26 06:00AM	Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 (Business Wire)
May-26-26 06:00AM	Personalis to Highlight Breadth of NeXT Personal Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium (Business Wire) +5.55%
May-20-26 06:00AM	Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring (Business Wire) +12.93%
May-14-26 04:01PM	Personalis to Participate in Upcoming Investor Events (Business Wire) +5.01% -5.22%
May-13-26 06:00AM	Personalis Receives Medicare Coverage for NeXT Personal for Immunotherapy Monitoring Across Late-stage Solid Tumors (Business Wire) +5.79%
May-07-26 04:53PM	Personalis: Q1 Earnings Snapshot (Associated Press)
04:01PM	Personalis Reports First Quarter Results and Recent Highlights (Business Wire)
Apr-23-26 04:01PM	Personalis to Announce First Quarter 2026 Financial Results (Business Wire) -6.50%
Apr-21-26 06:00AM	Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 (Business Wire)
Apr-13-26 06:00AM	Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 (Business Wire)
Apr-01-26 04:01PM	Personalis to Participate in the 25th Annual Needham Virtual Conference (Business Wire)
Mar-17-26 04:00PM	Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption (Business Wire)
Mar-12-26 06:00AM	Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal (Business Wire) -17.11%
Feb-27-26 04:30AM	Personalis Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... (GuruFocus.com)
Feb-26-26 05:30PM	Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +8.66%
04:26PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
Feb-24-26 07:30PM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-17-26 04:01PM	Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference (Business Wire) +5.02%
Feb-12-26 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -5.73%
Feb-10-26 09:18AM	Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test (Benzinga) +10.09%
06:00AM	Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance (Business Wire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool) -9.67%
Feb-02-26 08:18PM	Personalis, Inc. (PSNL): A Bull Case Theory (Insider Monkey)
06:00AM	Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Jan-28-26 04:01PM	Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-12-26 04:00PM	Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker (Business Wire) +5.80%
Jan-08-26 08:00AM	Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire) -10.43%
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 12:19PM	Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) (Insider Monkey)
Dec-17-25 06:00AM	Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Dec-11-25 09:00AM	New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer (Business Wire)
Nov-18-25 04:01PM	Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire) +8.14%
Nov-05-25 12:11AM	Personalis Inc (PSNL) Q3 2025 Earnings Call Highlights: Strong Clinical Adoption Amid Revenue ... (GuruFocus.com) -12.26%
Nov-04-25 05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:51AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q3 2025 Result (GuruFocus.com) -6.64%
Oct-21-25 04:01PM	Personalis to Announce Third Quarter 2025 Financial Results (Business Wire) -5.43% -6.74%
Oct-17-25 03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks) -11.19%
Oct-16-25 09:00AM	Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing (Business Wire) +20.52%
Sep-15-25 05:35PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks) +13.17%
Sep-10-25 04:05PM	CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test (Business Wire)
Sep-03-25 04:05PM	Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing (Business Wire)
Aug-27-25 04:01PM	Personalis to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 09:35AM	Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) (Zacks) +5.69%
Aug-12-25 09:35AM	After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) (Zacks)
Aug-08-25 12:00PM	All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy (Zacks)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-05-25 04:10PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance) -21.90%
04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 09:58AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q2 2025 Result (GuruFocus.com)
Jul-22-25 04:01PM	Personalis to Announce Second Quarter 2025 Financial Results (Business Wire) +5.13%
Jul-18-25 04:00PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
Jul-09-25 04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-03-25 07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-17-25 10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-03-25 04:00PM	Personalis' NeXT Personal Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO (Business Wire) +5.53%
Jun-02-25 04:00PM	New Data Shows NeXT Personal Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse (Business Wire)
May-22-25 06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection (Business Wire)
May-14-25 04:01PM	Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference (Business Wire) -6.23%
May-07-25 03:23AM	Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +21.00%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hall Christopher M	Chief Executive Officer	Nov 03 '26	Sale	15.87	29,112	462,007	199,415	Nov 04 04:15 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Sep 18 '26	Sale	16.22	2,068	33,543	90,257	Sep 22 04:10 PM
Chen Richard	President and CMO	Sep 18 '26	Sale	16.22	3,998	64,848	169,882	Sep 22 04:10 PM
Hall Christopher M	Chief Executive Officer	Sep 18 '26	Sale	16.22	7,459	120,985	228,527	Sep 22 04:10 PM
Tachibana Aaron	CFO AND COO	Sep 18 '26	Sale	16.22	2,931	47,541	195,902	Sep 22 04:10 PM
Chen Richard	President and CMO	Jul 15 '26	Option Exercise	2.44	100,000	244,000	273,880	Jul 15 09:27 PM
Chen Richard	President and CMO	Jul 15 '26	Sale	15.15	100,000	1,515,000	173,880	Jul 15 09:27 PM
RICHARD CHEN	Officer	Jul 15 '26	Proposed Sale	15.03	100,000	1,503,000		Jul 15 04:24 PM
Hall Christopher M	Chief Executive Officer	Jul 09 '26	Option Exercise	1.61	100,000	161,000	335,986	Jul 09 08:46 PM
Hall Christopher M	Chief Executive Officer	Jul 09 '26	Sale	15.08	100,000	1,508,000	235,986	Jul 09 08:46 PM
Chris Hall	Director	Jul 09 '26	Proposed Sale	14.11	100,000	1,411,000		Jul 09 04:26 PM
Tachibana Aaron	CFO AND COO	Jun 29 '26	Option Exercise	5.32	4,982	26,504	203,815	Jun 29 05:50 PM
Tachibana Aaron	CFO AND COO	Jun 29 '26	Sale	14.00	4,982	69,748	198,833	Jun 29 05:50 PM
AARON TACHIBANA	Officer	Jun 29 '26	Proposed Sale	13.02	4,982	64,866		Jun 29 04:44 PM
Tachibana Aaron	CFO AND COO	Jun 26 '26	Option Exercise	7.48	51,251	383,370	250,084	Jun 26 07:56 PM
Tachibana Aaron	CFO AND COO	Jun 26 '26	Sale	13.18	51,251	675,488	198,833	Jun 26 07:56 PM
Hall Christopher M	Chief Executive Officer	Jun 26 '26	Option Exercise	1.61	100,000	161,000	335,986	Jun 26 07:49 PM
Hall Christopher M	Chief Executive Officer	Jun 26 '26	Sale	13.15	100,000	1,315,000	235,986	Jun 26 07:49 PM
AARON TACHIBANA	Officer	Jun 26 '26	Proposed Sale	12.59	51,251	645,250		Jun 26 04:25 PM
Chris Hall	Director	Jun 26 '26	Proposed Sale	12.59	100,000	1,259,000		Jun 26 04:25 PM
Tachibana Aaron	CFO AND COO	Jun 04 '26	Option Exercise	9.16	40,000	366,400	238,833	Jun 05 08:19 PM
Tachibana Aaron	CFO AND COO	Jun 04 '26	Sale	12.01	40,000	480,400	198,833	Jun 05 08:19 PM
AARON TACHIBANA	Officer	Jun 04 '26	Proposed Sale	10.78	40,000	431,200		Jun 04 04:32 PM
Hall Christopher M	Chief Executive Officer	May 29 '26	Option Exercise	1.61	80,091	128,947	316,077	May 29 08:45 PM
Hall Christopher M	Chief Executive Officer	May 28 '26	Option Exercise	1.61	19,909	32,053	255,895	May 29 08:45 PM
Hall Christopher M	Chief Executive Officer	May 29 '26	Sale	11.02	80,091	882,603	235,986	May 29 08:45 PM
Hall Christopher M	Chief Executive Officer	May 28 '26	Sale	11.02	19,909	219,397	235,986	May 29 08:45 PM
Tachibana Aaron	CFO AND COO	May 29 '26	Option Exercise	9.16	38,799	355,399	237,632	May 29 08:27 PM
Tachibana Aaron	CFO AND COO	May 29 '26	Sale	11.58	38,799	449,292	198,833	May 29 08:27 PM
AARON TACHIBANA	Officer	May 29 '26	Proposed Sale	10.98	38,799	426,013		May 29 04:25 PM
CHRISTOPHER HALL	Director	May 28 '26	Proposed Sale	9.49	100,000	949,000		May 28 04:38 PM
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Option Exercise	9.16	1,201	11,001	165,659	Jan 23 06:03 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Sale	11.50	1,201	13,812	164,458	Jan 23 06:03 PM
AARON L TACHIBANA	Officer	Jan 22 '26	Proposed Sale	9.65	40,000	386,000		Jan 22 04:34 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Option Exercise	9.16	103,668	949,599	268,126	Nov 28 05:09 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Sale	10.78	103,668	1,117,541	164,458	Nov 28 05:09 PM
AARON L TACHIBANA	Officer	Nov 25 '25	Proposed Sale	9.99	103,668	1,035,643		Nov 25 04:51 PM

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

CEO & DirectorMr. Christopher M. Hall

M.S.Dr. Richard Chen M.D.

CFO & COOMr. Aaron L. Tachibana

Ph.D.Dr. Russ B. Altman M.D.

FRCPDr. Euan Angus Ashley DPHIL

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSNL

Personalis Inc

Upgrade your Finviz experience